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Abstract
C1q/TNF-related protein 13 (CTRP13), a hormone secreted by adipose tissue (adipokines), helps regulate glucose
metabolism in peripheral tissues. We previously reported that CTRP13 expression is increased in obese and hyperphagic
leptin-deficient mice, suggesting that it may modulate food intake and body weight. CTRP13 is also expressed in the
brain, although its role in modulating whole-body energy balance remains unknown. Here, we show that CTRP13 is
a novel anorexigenic factor in the mouse brain. Quantitative PCR demonstrated that food restriction downregulates
Ctrp13 expression in mouse hypothalamus, while high-fat feeding upregulates expression. Central administration of
recombinant CTRP13 suppressed food intake and reduced body weight in mice. Further, CTRP13 and the orexigenic
neuropeptide agouti-related protein (AgRP) reciprocally regulate each other’s expression in the hypothalamus: central
delivery of CTRP13 suppressed Agrp expression, while delivery of AgRP increased Ctrp13 expression. Food restriction
alone reduced Ctrp13 and increased orexigenic neuropeptide gene (Npy and Agrp) expression in the hypothalamus; in
contrast, when food restriction was coupled to enhanced physical activity in an activity-based anorexia (ABA) mouse
model, hypothalamic expression of both Ctrp13 and Agrp were upregulated. Taken together, these results suggest that
CTRP13 and AgRP form a hypothalamic feedback loop to modulate food intake and that this neural circuit may be
disrupted in an anorexic-like condition.
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Introduction
The hypothalamus plays a central role in integrating hormonal
and neural signaling pathways to modulate food intake and body
weight [1]. Neurons in the arcuate nucleus of the hypothalamus
are particularly important to this process. For example, neurons in
the arcuate nucleus respond to leptin, a hormone secreted by
adipocytes (known as an adipokine) in proportion to fat mass, to
suppress food intake [2]. Different populations of neurons in the
arcuate nucleus variably influence behavior: activation of neuro-
peptide Y/agouti-related protein (NPY/AgRP)-expressing neu-
rons promote food intake; activation of pro-opiomelanocortin/
cocaine- and amphetamine-regulated transcript (POMC/CART)-
expressing neurons suppress food intake [1]. Interestingly,
individuals diagnosed with the eating disorder anorexia nervosa
(AN) have increased circulating levels of AgRP [3,4], and
a polymorphism in the coding region of AgRP is associated with
AN [5]. Further, leptin and another widely-studied adipokine,
adiponectin, act in the hypothalamus to regulate body weight
[6,7,8]. Indeed, plasma leptin levels decrease in an anorexic state
[9], while circulating levels of adiponectin vary depending on the
type of AN [10,11,12,13].
We have recently identified and characterized a novel and
conserved family of secreted hormones, the C1q/TNF-related
proteins (CTRP1-15) [14,15,16,17,18,19,20]. Each CTRP has
a unique tissue expression profile, and several have been shown to
play important and distinct roles in regulating glucose and fatty
acid metabolism [17,18,19,21,22]. Adipose tissues and the brain
predominantly express CTRP13, and circulating levels of
CTRP13 are increased in leptin-deficient obese (ob/ob) hyper-
phagic mice [18]. Recombinant CTRP13 promotes glucose
uptake in cultured myotubes, hepatocytes, and adipocytes and
ameliorates fatty acid-induced insulin resistance in cultured
hepatocytes by suppressing lipid-induced stress signaling (i.e.,
JNK) [18], suggesting that increases in CTRP13 in vivo may be
a compensatory response to hyperglycemia. While the action of
CTRP13 on peripheral tissues has been demonstrated, its potential
role in regulating metabolism in the central nervous system (CNS)
remains unknown.
Here, we provide evidence that CTRP13 acts in the brain as an
anorexigenic signal to modulate food intake and body weight. Our
in vivo results suggest that CTRP13 and AgRP form a neural
feedback loop to modulate food intake and that this feedback
mechanism is disrupted in an activity-based anorexia (ABA) mouse
model. These results have implications for CTPR13 in un-
derstanding AN, a complex but poorly understood eating disorder
in humans.
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Materials and Methods
Animals
Wild-type (WT) male C57BL/6J mice (6–8 weeks old, The
Jackson Laboratories, Bar Harbor, ME) were used for these
studies. The neural circuitry of the hypothalamus has been largely
investigated in male mice. The primary goal of this study was to
characterize the central effects of CTRP13 on food intake and
peripheral energy metabolism. We chose to utilize male mice in
our current study so that we can better relate our results to prior
published studies with regard to alterations in neural circuitry
induced by central administration of recombinant CTRP13. Mice
were given ad libitum access to water and standard rodent
laboratory chow (2018, Harland-Teklad) and housed under
a 12:12 hour dark:light cycle. Diet-induced obese (DIO) male
C57BL/6 mice (The Jackson Laboratories) were fed a 60% high-
fat diet (HFD; Research Diets; D12492) for 8 weeks after weaning.
Age-matched chow-fed controls were also purchased from The
Jackson Laboratories. The studies were conducted using WT male
mice fed a standard rodent laboratory chow, except for the
neuropeptide analysis, which utilized DIO male mice. All studies
accorded with the recommendations in the Guide for the Care and
Use of Laboratory Animals of the National Institutes of Health. All
animal experiments were approved by the Animal Care and Use
Committee of The Johns Hopkins University School of Medicine
(protocol number MO11M49).
Activity-based Anorexia Paradigm and Metabolic
Measurements
Animals were individually housed in 40 cm640 cm630 cm
clear plexiglass cages, which were used to measure all metabolic
parameters. Animals received four days for adaptation to in-
dividual housing prior to the start of the experiment. CLAMS
(Comprehensive Laboratory Animal Monitoring System) (Colum-
bus Instruments, Columbus, OH) was used to measure body
weight, whole-body metabolism [VO2, VCO2, respiratory ex-
change ratio (RER), and energy expenditure (EE)], ambulatory
activity, running wheel activity, water consumption, and food
intake. We adapted the rat ABA paradigm [23,24,25] to our
present mouse study. As a control, the ad libitum group (AL) was
provided access to standard laboratory chow with no running
wheel. The running wheel (RW) group was provided ad libitum
access to standard laboratory chow and free access to a running
wheel. The food restricted (FR) group was allowed 2 h of access to
standard laboratory chow each day at the beginning of the dark
cycle (days 1–5), with no access to a running wheel. The ABA
group was allowed 2 h of access to standard laboratory chow each
day at the beginning of the dark cycle (days 1–5), as well as free
access to a running wheel. All CLAMS data presented represent
the average 24-h value collected on days 4 and 5. Sera were
collected from tail bleeds on day 5 for immunoblot analysis of
CTRP13. Later, mice from the FR and ABA groups were allowed
4 h of access to standard laboratory chow each day at the
beginning of the dark cycle for an additional 9 days (days 6–14).
The body weight, food intake, and metabolic data presented in the
results section were collected during the first week of exposure to
the ABA paradigm, and metabolic data collected after the first
seven days are not shown. After the second week of exposure to
the ABA paradigm, hypothalami were then collected for real-time
PCR analysis of Ctrp13 and neuropeptide gene expression.
Recombinant Protein Purification
Full-length recombinant CTRP13 with a C-terminal FLAG
epitope tag (DYKDDDDK) was expressed in HEK 293 cells
(GripTiteTM 293 cell line from Invitrogen, Carlsbad, CA).
Expression of recombinant protein in mammalian cells was
critically important to ensure that all proper posttranslational
modifications of CTRP13 and its assembly into a higher-order
oligomeric form were preserved [18]. Serum-free conditioned
media (Opti-MEM, Invitrogen) containing the secreted CTRP13
was purified as previously described [18]. Purified proteins were
dialyzed against 20 mM Hepes buffer (pH 8.0) containing
135 mM NaCl in a 10 kDa cut-off Slide-A-Lyzer (Thermo Fisher
Scientific, Waltham, MA). Protein concentration was determined
using a Coomassie Plus protein assay reagent (Thermo Fisher
Scientific, Rockville, MD), and samples were stored at 280uC.
Stereotaxic Cannulation and Recombinant Protein
Injection
A unilateral cannula was implanted into the lateral ventricle of
the brain as previously described [26]. Only wild-type C57BL/6
male mice were cannulated. None of the ABA mice were
cannulated or injected with recombinant protein. The correct
placement of the cannula was verified by intracerebroventricular
(ICV) injection of 2 mL of NPY (a total of 2 nmol was
administered per mouse) (American Peptide Company, Sunnyvale,
CA). A 1-h food intake test was given during the light cycle, with
an approximate 40% increase in food intake relative to saline
injection considered successful. Prior to recombinant protein
injection, mice were individually housed in indirect calorimetry
metabolic chambers (CLAMS) to allow adaptation for 4 days. Two
mL of recombinant protein (150 ng/mL) were ICV injected at the
beginning of the dark cycle and body weight, food intake, and
physical activity was measured over a 24-h period after protein
injection. Vehicle [20 mM Hepes (pH 8.0) containing 135 mM
NaCl] was used as control in all ICV injection experiments.
RNA Extraction and Quantitative Real-time PCR
Using the anterior commisure and the oculomotor nerve as
neuroanatomical markers, adult mouse hypothalami were dissect-
ed in phosphate buffered saline solution. Total RNA was extracted
using the RNeasy Midi kit (Qiagen, Valencia, CA). cDNA was
generated using SuperScriptH II Reverse Transcriptase (Invitro-
gen) and random hexamers from 1 mg of RNA. The default PCR
protocol was performed on an Applied Biosystems Prism 7500
Sequence Detection System using SyBRH Green PCR Master Mix
(Applied Biosystems, Carlsbad, CA). The qPCR output provided
Figure 1. Hypothalamic CTRP13 expression increased in mice
fed a high-fat diet (HFD). Food was removed for 2 h before
hypothalami were harvested from mice fed an HFD (n= 5) or from mice
fed a standard chow diet (n = 4). mRNA levels were measured using
quantitative real-time PCR. Data are means 6 SEM,*P,0.05.
doi:10.1371/journal.pone.0062862.g001
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a Ct value for the threshold cycle and the DCt value was obtained
by normalizing the data to 18S rRNA. The DDCt value (relative
expression level) was generated by normalizing to the average
control value. Primers used included: Nenf forward 59-
TCTGTAGCCGCTCTATCTGG-39 and reverse 59-
GTGTCGTG AGTGAGGTCTGC-39; AgRP forward 59-ATGC-
TAGGTAACAAGCGAATGG-39 and reverse 59-CAGACTTA-
GACCTGGGAACTCT-39; Npy forward 59-CTAGGTAA-
CAAGCGAATGG-39 and reverse 59-
TGTCGCAGAGCGGAGTAGTAT-39; 18 S rRNA forward 59-
GCAATTATTCC CCATGAACG-39 and reverse 59-
GGCCTCACTAAACCATCCAA-39.
Immunoblot Analysis
Rabbit polyclonal anti-CTRP13 antibody directed against the
C-terminal globular domain was generated as previously described
[18]. One mL-equivalent serum samples were suspended in
NuPAGE LDS sample buffer and heated for 5 minutes at 90uC.
Samples were electrophoresed on 10% BisTris NuPAGE gels
(Invitrogen, Carlsbad, CA), transferred to 0.2 mm Protran BA83
nitrocellulose membranes (GE Healthcare, Piscataway, NJ), and
probed with the CTRP13 primary antibody and appropriate
HRP-conjugated secondary antibody. Bands were visualized with
Immobilon Western HRP substrate peroxide solution (Millipore,
Billerica, MA), captured with MultiImage III FluorChemH Q
(Alpha Innotech, San Leandro, CA), and quantified using
Alphaview Software (Alpha Innotech).
Statistical Analysis
All value comparisons were made using either a t-test, one-way
ANOVA or repeated measures ANOVA (Statistica v.8.0, Tulsa,
OK). Values reported are means6SEM. P,0.05 was considered
statistically significant.
Results
Diet-induced Obesity Affects CTRP13 Transcript Levels in
the Hypothalamus
In our previous study, the expression levels of Ctrp13 were
measured only in the periphery [18]. Here, Ctrp13 transcript levels
were measured in the CNS, specifically the hypothalamus, under
metabolic stress induced by high-fat feeding in DIO mice. As
measured by quantitative real-time PCR, Ctrp13 expression in the
hypothalamus increased in mice fed a HFD relative to mice fed
Figure 2. Central administration of recombinant CTRP13 suppressed food intake and reduced body weight. A) Body weight, B) food
intake, and C) respiratory exchange ratio (RER) were measured by CLAMS 24 h after ICV injection of recombinant CTRP13 (n = 8) or vehicle control
(n = 7). D) Ambulatory activity levels over a 20-h period were also measured after ICV injection of CTRP13 (n = 8) relative to vehicle-injected (n = 7)
mice. Data are means 6 SEM,*P,0.05.
doi:10.1371/journal.pone.0062862.g002
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Figure 3. Metabolic parameters and behavior associated with activity-based anorexia (ABA) paradigm. A) Body weight, B) food intake,
C) water intake, D) ambulatory activity, E) running wheel activity, F) respiratory exchange ratio (RER), G) VO2, H) VCO2, I) Heat/energy expenditure, and
J) blood glucose were measured in AL (n = 5), RW (n = 5), FR (n = 6) and ABA (n= 5) groups by CLAMS. Values represent means6 SEM, *P,0.05 vs. AL,
averaged over paradigm exposure days 4 and 5, and day 5 for blood glucose values. (AL = ad libitum food access; RW= ad libitum food access and free
access to a running wheel; FR = 2-h food access per day; ABA=2-h food access per day and free access to a running wheel).
doi:10.1371/journal.pone.0062862.g003
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a standard chow diet (Figure 1). Given the importance of the
hypothalamus in controlling food intake and peripheral energy
metabolism [1], this result suggests that hypothalamic expression
of Ctrp13 may be physiologically relevant in the context of food
intake and body weight regulation.
Central Administration of Recombinant CTRP13
Suppresses Food Intake and Body Weight
To address whether the upregulated expression of hypothalamic
CTRP13 in HFD-fed mice represents a possible compensatory
response to an altered state of energy balance, we injected purified
recombinant CTRP13 or vehicle control into the lateral ventricle
of chow-fed mice to determine its potential appetite-regulating
function in the brain. ICV administration of a single dose of
recombinant CTRP13 (2 mL of 150 ng/mL) significantly de-
creased body weight (8%) (Figure 2A) and suppressed food intake
(56%) (Figure 2B) over a 24-h period, relative to vehicle-injected
controls. RER also significantly decreased (8%) in CTRP13-
administered mice relative to vehicle-injected controls (Figure 2C).
Previous studies have shown that a 0.10 ratio reduction in RER
reduces O2 consumption by carbohydrate oxidation by,34% and
increases O2 consumption by fat oxidation by ,34% [27].
CTRP13-induced suppression of food intake could result in
greater fatty acid release from adipocytes, supplying substrates for
fat oxidation in the liver and skeletal muscle and possibly
accounting for the decreased RER. Importantly, there was no
significant change in physical activity levels (over a 20-h period)
between the CTRP13- and vehicle-injected groups (Figure 2D),
suggesting that the central effect of CTRP13 in appetite
suppression (over a similar time period) was not due to non-
Figure 4. Activity-based anorexia (ABA) paradigm reduced
circulating levels of CTRP13. Immunoblot of serum levels of CTRP13
in AL (n = 5), RW (n= 5), FR (n = 6), and ABA (n = 5) groups were
quantified. CTRP13 serum levels were decreased in the RW, FR, and ABA
groups relative to the AL group. Values shown are means 6 SEM,
*P,0.05 vs. AL. (AL = ad libitum food access; RW= ad libitum food access
and free access to a running wheel; FR = 2-h food access per day;
ABA= 2-h food access per day and free access to a running wheel).
doi:10.1371/journal.pone.0062862.g004
Figure 5. Comparison of behavior and metabolic profiles of mice ICV-injected with vehicle or CTRP13 and mice subjected to the
activity-based anorexia (ABA) paradigm. A) Body weight, B) food intake, C) VO2, D) VCO2, E) respiratory exchange ratio (RER), and F) blood
glucose were measured by CLAMS in ABA (n = 5), CTRP13-injected (n = 8), and vehicle-injected control (n = 7) mice. Data are means 6 SEM,*P,0.05.
doi:10.1371/journal.pone.0062862.g005
Central Action of CTRP13
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specific physical illness induced by central delivery of the
recombinant protein.
Establishment of an Activity-based Anorexia (ABA)
Mouse Model
Severe restriction of food intake is characteristic of AN, and
hyperactivity is common among these individuals [28,29]. Animal
models of ABA mimic core features of AN in humans, including
food restriction, reduced body weight, and enhanced physical
activity [24,25,30]. We adapted the rat ABA paradigms [23,24,25]
to our present mouse study. Variations in ABA paradigm or mouse
strain or sex can affect food intake and body weight loss
[31,32,33,34,35,36]. Development of ABA in mice can also be
modulated by the length of time that food intake is permitted over
a 24-h period (e.g., 1, 2, 4, or 6 h), and the time at which food is
delivered for consumption (e.g., light or dark cycle)
[31,32,33,34,35,36]. In the present study, mice were maintained
on the ABA paradigm for a longer period of time to validate the
paradigm and to characterize alterations in neural circuitry due to
long-term exposure to ABA (i.e., two weeks rather than one).
After being exposed to the ABA paradigm group variables for
five days, the FR and ABA groups were allowed 2 h access to food
per day. Mice in these two groups demonstrated decreased body
weight (Figure 3A), decreased food intake (Figure 3B), no change
in cumulative water intake (Figure 3C), increased ambulatory
activity (Figure 3D), decreased RER (Figure 3F), decreased basal
metabolic rate (VO2 and VCO2) (Figure 3G and H), decreased
heat/energy expenditure (Figure 3I), and decreased blood glucose
(Figure 3J) relative to the AL group. The ABA group demonstrat-
ed increased running wheel activity relative to the RW group
(Figure 3E). No differences were observed between the FR and
ABA groups on the first two days of the paradigm (data not
shown). However, from day three we observed differences in body
weight, food intake, and blood glucose between the FR and ABA
groups (Figures 3A, B, and J, respectively). These data indicated
that we established an anorexia-like mouse model (decreased food
intake and increased physical activity) by restricting food intake
while giving the mice free access to a running wheel. Western
blotting of sera harvested from these 4 groups of mice showed that
circulating levels of CTRP13 in the periphery were decreased
(,30%) in the ABA, FR, and RW groups relative to the AL group
Figure 6. Activity-based anorexia (ABA) paradigm altered hypothalamic Ctrp13 and neuropeptide gene expression. Quantitative real-
time PCR measured A) Agrp B) Ctrp13, and C) Npy mRNA levels in the hypothalamic of AL (n = 5), RW (n= 5), FR (n = 6), ABA (n = 5) and AL (n = 5) mice.
Data are means6 SEM,*P,0.05 vs. vehicle. (AL = ad libitum food access; RW= ad libitum food access and free access to a running wheel; FR = 2-h food
access per day; ABA= 2-h food access per day and free access to a running wheel).
doi:10.1371/journal.pone.0062862.g006
Figure 7. Reciprocal regulation of Ctrp13 and Agrp expression in the hypothalamus. A) Quantitative real-time PCR was used to measure
Ctrp13 expression in mice hypothalami after ICV injection of AgRP (n = 6) or vehicle control (n = 7). B) Quantitative real-time PCR was used to measure
Agrp expression in mice hypothalami after ICV injection of CTRP13 (n = 6) or vehicle control (n = 7). Data are means 6 SEM,*P,0.05.
doi:10.1371/journal.pone.0062862.g007
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PLOS ONE | www.plosone.org 6 April 2013 | Volume 8 | Issue 4 | e62862
(Figure 4). Decreased food intake and body weight were observed
in both the ABA and FR groups, but not the RW group,
compared to AL, despite decreased serum levels of CTRP13 in all
three groups. This suggests that other factors in addition to food
intake and body weight may influence peripheral CTRP13 levels.
CTRP13 administration In the Mouse CNS Demonstrates
a Phenotype Resembling ABA
We conducted a side-by-side comparison between non-cannu-
lated ABA mice, chow-fed mice injected centrally with vehicle
control, and chow-fed mice injected centrally with a single dose of
recombinant CTRP13 (2 mL of 150 ng/ml) by assessing whole-
body metabolic parameters and measuring random blood glucose
levels. A lower RER is indicative of a greater reliance on fatty
acids as substrates for energy production and is expected when
mice have a suppressed food intake. ICV delivery of recombinant
CTRP13 significantly reduced body weight (Figure 5A), food
intake (Figure 5B), VCO2 (Figure 5 D), RER (Figure 5E), and
blood glucose levels (Figure 5F) relative to vehicle-injected
controls, without affecting VO2 (Figure 5C). Similarly, ABA mice
also demonstrated decreases in all the same metabolic parameters.
Together, these data support a satiety role of CTRP13 in the
CNS.
Altered Expression of CTRP13 and Orexigenic
Neuropeptide Genes in the Hypothalamus of ABA Mice
Given the important role of orexigenic neuropeptides (NPY and
AgRP) in the hypothalamus to modulate ingestive behavior [1], we
assessed their expression levels and that of CTRP13 in the 4 groups
of mice after two weeks of exposure to AL (ad libitum), RW (ad
libitum with running wheel), FR (food restriction), or ABA (food
restriction with running wheel) paradigms. Under the condition of
negative energy balance (e.g., fasted or food-restricted mice), Agrp
expression levels in the hypothalamus increase to stimulate food
consumption [1]. Real-time PCR detected significantly increased
Npy and Agrp expression in the hypothalamus of food-restricted FR
and ABA groups relative to the AL group (Figure 6A–B). Both FR
and RW groups had significantly decreased Ctrp13 expression in
the hypothalamus relative to the AL group (Figure 6C). This result
was consistent with decreased CTRP13 serum levels observed for
both the FR and RW groups (Figure 4), as expected given the
satiety effect of CTRP13 (Figure 2 and 5). However, hypothalamic
Ctrp13 expression in ABA mice significantly increased relative to
the AL group, despite comparable reductions in body weight in
both FR and ABA groups due to food restriction and decreased
serum CTRP13 levels. Persistently upregulated Ctrp13 expression
in food-restricted ABA mice, despite enhanced Agrp expression,
suggests that the appetite-regulatory neural circuit involving
CTPR13 may be dysregulated in the anorexic-like condition and
that this may be independent of circulating levels in plasma.
Reciprocal Regulation of AgRP and CTRP13 Expression in
the Hypothalamus
AgRP promotes food intake, whereas CTRP13, when delivered
centrally, suppresses food intake. We asked whether AgRP
regulates the hypothalamic expression of Ctrp13 and vice versa.
Recombinant AgRP was delivered into the lateral ventricle of
cannulated mice via ICV injection. Following injection, mice were
allowed to consume food for 2 h and then were removed from
food for 2 h, after which hypothalami were harvested for
quantitative real-time PCR analysis. Central administration of
the orexigenic neuropeptide AgRP significantly elevated Ctrp13
transcript levels in the hypothalamus relative to vehicle-injected
controls (Figure 7A). Alternatively, recombinant CTRP13 was
injected into the lateral ventricle of cannulated mice and
hypothalami were collected 3 h after injection. Recombinant
CTRP13 significantly reduced Agrp expression in the hypothala-
mus relative to vehicle-injected controls (Figure 7B). These data
suggest that the satiety effect of CTRP13 in the brain was due to
its ability to acutely reduce expression of orexigenic neuropeptide
AgRP, which promotes food intake. Thus, AgRP and CTRP13
reciprocally regulate expression of one another in the hypothal-
amus; together, these results suggest that CTRP13 and AgRP form
a hypothalamic feedback loop to modulate food intake and energy
balance and that this feedback circuit appears to be disrupted in
the anorexic-like mouse model.
Discussion
Eating disorders–which include AN, bulimia nervosa, and
binge-eating disorder–are serious public health problems, although
the molecular underpinnings of these disorders remain largely
unknown [37,38]. High heritability rates and complex patterns of
polygenic inheritance underscore the genetic determinants of these
complex behavioral disorders [39,40]. Although distortions of
body image are prevalent among individuals with AN [41], central
and peripheral factors may also initiate the development of this
disease [9,13,37,38].
Here, we provide the first in vivo evidence that CTRP13
functions as a novel anorexigenic factor in the hypothalamus to
modulate food intake and body weight. Hypothalamic Ctrp13
expression is dynamically regulated by energy state: 2-week food
restriction suppressed expression, but excessive caloric intake from
high-fat feeding and exposure to the ABA paradigm enhanced
Ctrp13 expression. Central administration of recombinant
CTRP13 suppressed food intake and reduced body weight, in
part by decreasing hypothalamic expression of the orexigenic
neuropeptide AgRP. In addition, CTRP13 and AgRP regulate
one another: central administration of AgRP enhanced Ctrp13
expression in the hypothalamus, while central administration of
CTRP13 suppressed Agrp expression. Thus, when AgRP upregu-
lates hypothalamic CTRP13 expression, it may, in turn, act to
limit AgRP-mediated food intake. Together, these results suggest
that CTRP13 and AgRP form a feedback mechanism to modulate
whole-body energy balance.
Patients diagnosed with AN demonstrate a 30–80% increase in
physical activity levels [28,29]. The ABA paradigm used in this
study mimics the food restriction and enhanced physical activity
observed in anorexic individuals. Patients with AN have decreased
body weight, decreased circulating leptin levels, and increased
AgRP levels [4]. Likewise, both rats and mice exposed to the ABA
paradigm have decreased body weight, decreased plasma leptin
levels, and increased hypothalamic AgRP levels [23,24,25,33].
Human and mouse CTRP13 share 96% amino acid identity at the
presumed functional C1q domain and share tissue expression
profiles (predominantly adipose tissue and the brain) [18]. While
this study demonstrates CTRP13’s function in the mouse CNS, it
is likely that CTRP13 also plays a similar role in the human CNS
to modulate food intake and body weight. Thus, our study
provides a rationale for further examination of CTRP13 expression
and function in individuals with AN.
Using the ABA mouse model, we show that Agrp and Ctrp13
mRNA levels are simultaneously elevated in the hypothalamus.
During a state of negative energy balance, such as in FR mice, Agrp
expression increased and Ctrp13 expression decreased, in the
hypothalamus, consistent with their respective roles as orexigenic
and anorexigenic factors. In contrast, Agrp and Ctrp13 expression
Central Action of CTRP13
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both increased in the hypothalamus of ABA mice, despite an equal
degree of food restriction in both ABA and FR mice. These
observations suggest that the potential hypothalamic AgRP-
CTRP13 feedback loop is dysregulated in ABA mice. We
speculate that in an anorexic-like state, the hypothalamic neurons
may not appropriately respond to signals to alter Ctrp13
expression. Therefore, persistently high expression of both
orexigenic (AgRP) and anorexigenic (CTRP13) genes in an
anorexic-like state may be causally linked to the pathogenesis of
AN.
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